secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-040009
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025
------------------------------------------------------------------

- Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.
- Cash $21.3M, down from $35.6M at Dec 2022; projected runway into Q1 2025.
- PUR1900 Phase 2b in ABPA ongoing; topline data expected H2 2024.
- PUR3100 IND cleared for Phase 2 in acute migraine; study start contingent on financing.
- PUR1800 Phase 1b completed; seeking partnership for Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/0001493152-23-040009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer